WO2012036344A1 - Composition alimentaire de coupe-faim comportant un composé spécifique en tant que principe actif - Google Patents

Composition alimentaire de coupe-faim comportant un composé spécifique en tant que principe actif Download PDF

Info

Publication number
WO2012036344A1
WO2012036344A1 PCT/KR2010/008111 KR2010008111W WO2012036344A1 WO 2012036344 A1 WO2012036344 A1 WO 2012036344A1 KR 2010008111 W KR2010008111 W KR 2010008111W WO 2012036344 A1 WO2012036344 A1 WO 2012036344A1
Authority
WO
WIPO (PCT)
Prior art keywords
appetite
ghrelin
ginsenoside
composition
food
Prior art date
Application number
PCT/KR2010/008111
Other languages
English (en)
Korean (ko)
Inventor
김인호
한대석
이창호
조승목
Original Assignee
한국식품연구원
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020100091517A external-priority patent/KR101155426B1/ko
Priority claimed from KR1020100108541A external-priority patent/KR101250198B1/ko
Application filed by 한국식품연구원 filed Critical 한국식품연구원
Publication of WO2012036344A1 publication Critical patent/WO2012036344A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Definitions

  • the present invention relates to an appetite suppressant food ingredient composition
  • an appetite suppressant food ingredient composition comprising a specific compound as an active ingredient, more specifically hesperetin (hesperetin), ginsenoside-Rb1 (ginsenoside-Rb1), 3-hydroxyflavone (3- hydroxyflavone, hesperidin, ginsenoside-Rg1, beta-D-glucan, ⁇ -D-glucan, rutin, flavonone, naringin, melatonin ( It relates to an appetite suppressing composition and at least one functional food for suppressing appetite containing at least one component selected from the group consisting of melatonin, quercetin and ascorbic acid.
  • Obesity is the highest in the United States (32% of the population), with a body mass index (BMI) of 30 or higher, and Mexico, 30%, the UK, 23%, Greece, Australia, and New Zealand, 21%. have. In Korea, 1.5% to 2 million people, 3.5% of the total population, are obese, but the population of obesity is increasing very rapidly due to westernization and diversification of dietary life.
  • BMI body mass index
  • Obesity has led to adult disease, including diabetes, hypertension, cardiovascular disease, cancer and mental distress, to some of the causes of death, and also affects national productivity, activity and competitiveness.
  • obesity of children and adolescents in Korea which has undergone many changes in their diet and educational environment, is increasing rapidly, and the recovery of treatment after the onset of pediatric diabetes is not easy, causing serious severity.
  • Obesity-related treatments have been tried in various ways such as drug administration, exercise, diet, psychotherapy, and surgery, but it is difficult to improve by specific methods, and complex treatments and patient will are important.
  • drug administration the drug was developed on the basis of lipolysis or digestive enzyme inhibition, but it has side effects.
  • appetite control appetite control to fundamentally regulate the intake of food
  • appetite suppression by the food ingredient composition as a first attempt is meaningful as an invention with novelty, originality and progressiveness
  • reductil has been released as a drug to control obesity due to appetite control, but it is required to access food or natural products with side effects such as loss of appetite, insomnia, depression, and blood pressure. Therefore, there is a need for a composition for appetite suppression that can contribute to suppression of obesity by creating a new value as an appetite suppressing food material while minimizing side effects.
  • the present invention first developed an appetite suppression method by a food ingredient composition as a means of preventing obesity, and in the method of demonstrating the appetite suppression effect, a test system for suppressing ghrelin that promotes appetite is first discovered in a cell differentiation degree. Therefore, food ingredients were applied and appetite suppression effects were scientifically verified.
  • Korean Patent Publication No. 2004-0097813 discloses an anti-obesity functional composition having three functions such as appetite suppression, body fat reduction, and bowel activation.
  • Korean Patent Publication No. 2004-0036111 discloses ginseng and polyphenol-based substances or bioflavonoids. Foods for improving lipid metabolism and anti-obesity including a powder or extract of a plant comprising a systemic substance have been disclosed, but differ from the appetite suppressing food ingredient composition of the present invention.
  • the present invention is derived from the above requirements, the present invention is desired to develop a functional material that can suppress the appetite, but many limitations due to safety problems such as limitations and side effects of body fat decomposition, digestion inhibition method nowadays, hesperetin, ginsenoside-Rb1, 3-hydroxyflavone, hesperidin, hesperidin and ginsenoside Ginsenoside-Rg1, beta-D-glucan, ⁇ -D-glucan, rutin, flavonone, naringin, melatonin, quercetin and ascorbic acid
  • the present invention was completed by developing an appetite suppressing composition containing at least one component selected from the group consisting of acid) as an active ingredient.
  • the present invention first developed an appetite suppression method by a food ingredient composition as a solution to obesity suppression, and also in the method of proving appetite suppression effect, by first discovering a test system that suppresses Ghrelin to promote appetite according to the degree of cell differentiation Food ingredients were applied and appetite suppression effects were scientifically verified.
  • the present invention is an active ingredient hesperetin (hesperetin), ginsenoside-Rb1 (ginsenoside-Rb1), 3-hydroxyflavone (3-hydroxyflavone), hesperidin (hesperidin), ginsenoside Ginsenoside-Rg1, beta-D-glucan, beta-D-glucan, rutin, flavonone, naringin, melatonin, quercetin and ascorbic acid It provides a composition for suppressing appetite containing at least one component selected from the group consisting of ascorbic acid).
  • hesperetin hesperetin
  • ginsenoside-Rb1 ginsenoside-Rb1
  • 3-hydroxyflavone 3-hydroxyflavone
  • hesperidin hesperidin
  • ginsenoside-Rg1 ginsenoside-Rg1
  • Beta-D-glucan rutin, flavonone, flanone, naringin, melatonin, quercetin and ascorbic acid
  • the appetite suppressant composition of the present invention is effective for suppressing appetite, and because it uses food ingredients, no side effects appear even after taking for a long time, and it is possible to secure safety, very useful in functional food industry for appetite suppression It will be an invention.
  • the method to prove the appetite suppression effect was the first to discover the ghrelin test system that promotes appetite, and to provide the first model to scientifically verify the appetite suppression effect by applying food ingredients according to the degree of cell differentiation.
  • FIG. 1 shows the concentration of ghrelin as a multinucleate differentiation inhibitory activity when 0.1 ⁇ g / ml of each food ingredient is added to human umbilical vein endothelial cell (HUVEC) cells.
  • HUVEC human umbilical vein endothelial cell
  • FIG. 2 shows the concentration of ghrelin as a multinucleate differentiation inhibitory activity when 1 or 10 ⁇ g / ml of each food ingredient is added to human umbilical vein endothelial cells (HUVEC) cells. .
  • HUVEC human umbilical vein endothelial cells
  • ginsenoside-Rb1 sibutramine (positive control)
  • 2 ascorbic acid
  • 3 beta-D-glucan
  • 4 hesperetin
  • 5 alpha-lipoic acid ( ⁇ ) -lipoic acid)
  • 6 serotonin
  • 7 melatonin
  • 8 alpha-tocopherol
  • 9 ginsenoside-Rb1
  • 10 ginsenoside-Rg1 (ginsenoside-Rg1)
  • 11 naringenin
  • FIG. 3 shows that each food ingredient is treated at 60 ° C., 80 ° C. and 100 ° C. for 5 minutes, and then food ingredients are added to human umbilical vein endothelial cells (HUVEC) cells, respectively, and the amount of ghrelin is measured. .
  • HUVEC human umbilical vein endothelial cells
  • Figure 4 is treated with each food ingredient at 60 °C, 80 °C and 100 °C for 5 minutes, and then added food ingredients to human umbilical vein endothelial cells (HUVEC) cells, respectively, the cell proliferation capacity and the amount of ghrelin (ghrelin) It is measured.
  • HUVEC human umbilical vein endothelial cells
  • ginsenoside-Rb1 sibutramine (positive control)
  • 2 ascorbic acid
  • 3 beta-D-glucan
  • 4 hesperetin
  • 5 alpha-lipoic acid ( ⁇ ) -lipoic acid)
  • 6 serotonin
  • 7 melatonin
  • 8 alpha-tocopherol
  • 9 ginsenoside-Rb1
  • 10 ginsenoside-Rg1 (ginsenoside-Rg1)
  • 11 naringenin
  • FIG. 5 shows that the food ingredients are added to human umbilical vein endothelial cells (HUVEC) cells after treatment of each food ingredient at pH 2, 5 and 7 within 5 minutes, respectively, and the amount of ghrelin is measured.
  • HUVEC human umbilical vein endothelial cells
  • FIG. 6 shows that each food ingredient is treated within 5 minutes at pH 2, 5, and 7, and then the food ingredient is added to human umbilical vein endothelial cells (HUVEC) cells to measure cell proliferation and ghrelin levels. It is.
  • HUVEC human umbilical vein endothelial cells
  • ginsenoside-Rb1 sibutramine (positive control)
  • 2 ascorbic acid
  • 3 beta-D-glucan
  • 4 hesperetin
  • 5 alpha-lipoic acid ( ⁇ ) -lipoic acid)
  • 6 serotonin
  • 7 melatonin
  • 8 alpha-tocopherol
  • 9 ginsenoside-Rb1
  • 10 ginsenoside-Rg1 (ginsenoside-Rg1)
  • 11 naringenin
  • Figure 7 shows the weight change and dietary intake of the rats in the normal diet (control), high fat diet (control), high fat diet + 3-hydroxyflavone (3-hydroxyflavone) administration group (A) respectively .
  • Figure 8 shows the rats in the normal diet group (normal), high fat diet (control), high fat diet + 3-hydroxyflavone (3-hydroxyflavone) administration group (A) and the activity of the rats, respectively.
  • the present invention is an active ingredient hesperetin (hesperetin), ginsenoside-Rb1 (ginsenoside-Rb1), 3-hydroxyflavone (3-hydroxyflavone), hesperidin (hesperidin), gin Ginsenoside-Rg1, beta-D-glucan, ⁇ -D-glucan, rutin, flavonone, naringin, melatonin, quercetin and ascorbate It provides a composition for suppressing appetite containing at least one component selected from the group consisting of acid (ascorbic acid).
  • the appetite suppression may be an effect of inhibiting the activity of ghrelin (ghrelin), an appetite-stimulating hormone.
  • the active ingredient included in the composition of the present invention may maintain ghrelin inhibitory activity even after 5 minutes treatment at a temperature of 60 ⁇ 100 °C. From this, the ghrelin inhibitory activity is maintained even when the food ingredient is heated, thereby indirectly confirming the possibility of maintaining appetite suppressing activity of the food ingredient during processing.
  • the active ingredient included in the composition of the present invention can maintain the ghrelin inhibitory activity even after 5 minutes treatment at pH 2 ⁇ 10. From this, it was indirectly determined that the appetite suppression effect was maintained overall by suppressing ghrelin activity even when ingesting food components in the body.
  • Appetite suppressing compositions of the present invention may include suitable carriers, excipients and diluents commonly used in the manufacture of pharmaceutical compositions.
  • compositions of the present invention may be used in the form of their pharmaceutically acceptable salts, and may be used alone or in combination with other pharmaceutically active compounds, as well as in a suitable collection.
  • the appetite suppressing composition according to the present invention is formulated in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols and the like, external preparations, suppositories, and sterile injectable solutions, respectively, according to a conventional method. Can be used.
  • Carriers, excipients and diluents that may be included in the appetite suppressant composition include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, Various compounds or mixtures, including cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, mineral oil and the like.
  • diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, and surfactants are usually used.
  • Solid preparations for oral administration include tablets, pills, powders, granules, capsules and the like, and such solid preparations include at least one excipient such as starch, calcium carbonate and sucrose in the ingredients. ) Or lactose, gelatin and the like are mixed.
  • lubricants such as magnesium stearate and talc are also used.
  • Oral liquid preparations include suspensions, solvents, emulsions, and syrups, and may include various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin.
  • Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories.
  • the non-aqueous solvent and suspending agent propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate and the like can be used.
  • As the base of the suppository witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
  • Preferred dosages of the appetite suppressant composition of the present invention vary depending on the condition and weight of the patient, the extent of the disease, the form of the drug, the route of administration and the duration, and may be appropriately selected by those skilled in the art.
  • the appetite suppressing composition of the present invention is preferably administered at 0.0001 to 100 mg / kg, preferably 0.001 to 100 mg / kg per day. Administration may be administered once a day or may be divided several times. The dosage does not limit the scope of the invention in any aspect.
  • the appetite suppressant composition of the present invention can be administered to various mammals such as mice, mice, livestock, humans. All modes of administration can be expected, for example by oral, rectal or intravenous, intramuscular, subcutaneous, intrauterine dural or intracerebroventricular injection.
  • the invention also relates to hesperetin, hesperetin, ginsenoside-Rb1, 3-hydroxyflavone, 3-hydroxyflavone, hesperidin, ginsenoside-Rg1, ginsenoside-Rg1, Beta-D-glucan, rutin, flavonone, flanone, naringin, melatonin, quercetin and ascorbic acid It provides a functional food for suppressing appetite containing at least one ingredient as an active ingredient.
  • the appetite suppressing composition of the present invention When used as a food additive, the appetite suppressing composition may be added as it is or used with other foods or food ingredients, and may be appropriately used according to a conventional method.
  • the blending amount of the active ingredient can be suitably determined according to the purpose of its use (prevention, health or therapeutic treatment). Generally, in the manufacture of food or beverages the components of the invention are added in an amount of up to 15 parts by weight, preferably up to 10 parts by weight relative to the raw materials. However, in the case of long-term intake for health and hygiene or health control, the amount may be below the above range, and the active ingredient may be used in an amount above the above range because there is no problem in terms of safety. .
  • Examples of the food to which the substance can be added include dairy products including meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums, ice cream, various soups, drinks, tea, drinks, Alcoholic beverages and vitamin complexes, and the like and include all foods in a conventional sense.
  • the functional beverage composition containing the meat suppressing composition of the present invention may contain various flavors, natural carbohydrates, and the like as additional components, as in general beverages.
  • the above-mentioned natural carbohydrates are glucose, monosaccharides such as fructose, disaccharides such as maltose and sucrose, and polysaccharides such as dextrin and cyclodextrin, sugar alcohols such as xylitol, sorbitol and erythritol.
  • sweetening agent natural sweetening agents such as tautin and stevia extract, synthetic sweetening agents such as saccharin and aspartame, and the like can be used.
  • the ratio of the natural carbohydrate is generally about 0.01 to 0.04 g, preferably about 0.02 to 0.03 g per 100 ml of the composition of the present invention.
  • the appetite suppressing composition of the present invention includes various nutrients, vitamins, electrolytes, flavoring agents, coloring agents, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, Alcohols, carbonating agents used in carbonated drinks, and the like.
  • the appetite suppressing composition of the present invention may contain a flesh for preparing natural fruit juice, fruit juice beverage and vegetable beverage. These components can be used independently or in combination. The proportion of such additives is not critical but is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the composition of the present invention.
  • the food ingredient for appetite suppression test system is to make it possible to obtain a single ingredient, and it is 3-hydroxyflavone, rutin, quercetin, flavonone, flavonone, Naringin, hesperidin, catechin, capsaicin, caffeine, theobromine, ascorbic acid, beta-D-glucan, ⁇ -D-glucan, Hesperetin, lipoic acid, serotonin, serotonin, melatonin, tocopherol, ginsenoside-Rb1, ginsenoside-Rg1, ginsenoside-Rg1, Naringenin and sibutramine (sibutramin, positive control) were obtained.
  • the target food ingredients were dissolved in DMSO, diluted and used for each concentration.
  • the final concentration of DMSO was 0.1% or less to prepare a cell test sample solution.
  • HUVEC human umbilical vein endothelial cells
  • EGM-2 medium FBS, Hydrocortisone, hFGF, VEGF.R3-IGF-1, Ascorbic acid, hEGF, GA-1000, Heparin
  • FBS Hydrocortisone
  • hFGF vascular endothelial growth factor
  • VEGF.R3-IGF-1 Ascorbic acid
  • hEGF GA-1000
  • Heparin Heparin
  • Samples for ghrelin analysis were separated into supernatant and cell lysate. After completion of the experiment, the recovered culture was centrifuged (3,000 rpm, 20 minutes, 4 °C) to recover only the supernatant, cell lysate was centrifuged for 10 minutes at 10000 rpm after separating the cells with Trypsin-EDTA. After removing the supernatant and preparing a cell lysate using a solution containing 1% of Triton X-100 in the obtained cells, the content of ghrelin was measured using a HUMAN unacylated ghrelin kit (SPI-Bio).
  • the method of measuring ghrelin was placed in a well of standard diluent buffer and 100 ul of sample, and 100 ul of anti-unacylated ghrelin-AChE tracer was added. After 3 hours of incubation at room temperature, the culture solution was completely removed and washed 5 times with diluted wash solution. After drying the plate, absorbance was measured at 405 nm after adding 200 ul of Ellman's reagent.
  • the inhibitory activity of ghrelin an appetite-stimulating hormone according to heating temperature, was investigated for food ingredient concentrations that had high inhibitory activity against ghrelin. After a certain amount of food ingredients were treated at 60 ° C., 80 ° C. and 100 ° C. for 5 minutes, and prepared at concentrations having high inhibitory activity against ghrelin, the cell proliferation ability and the amount of ghrelin were measured.
  • the ghrelin inhibitory activity was investigated according to the pH change of food ingredients under acidic, neutral and basic conditions. Each food solution was dipped in each pH solution at a concentration of 10% within 5 minutes, and then lyophilized to prepare a concentration having high inhibitory activity against ghrelin, and then the cell proliferation ability and the amount of ghrelin were measured.
  • mice were 4 weeks old C57BL / 6J male mice, and the day and night cycle (12 hours light / 12 hours night) was controlled and the indoor temperature was raised in the animal breeding room of 22 ⁇ 25 °C.
  • One week of adaptation mice were fed high fat diets supplemented with 40% bee tallow to normal diet for 8 weeks to induce the high fat diet group.
  • the experimental animals were divided into the normal group and the high-fat diet group, and the dietary intake and body weight were measured periodically.
  • 3-hydroxyflavone a food ingredient expected to have anti-obesity effect
  • S-mart program Pan Lab, Spain
  • a program that measures all movements of a given place using a computer sensor for 1 hour in a white matt acrylic box of 40 ⁇ 40 ⁇ 40 cm in width, length, and height.
  • the behavior of was measured after 3 weeks of food ingredient treatment.
  • the image obtained from the digital camera installed about 2.5m above the box is transferred to the computer and tracked according to the movement of the subject by recognizing the center point of the white subject image using the principle of contrasting the white subject against the black background. It was. Then, the trajectory of the movement of the test animal was quantified to quantify the distance moved.
  • Human umbilical vein endothelial cell (HUVEC) cells contain food ingredients (3-hydroxyflavone, rutin, quercetin, flavonone, naringin, hesperidin, When catechin, capsaicin, caffeine, and theobromine were added at 0.1 ⁇ g / ml, the concentration of ghrelin was measured by multinucleate differentiation inhibitory activity compared to the control. (FIG. 1). As a result, the concentration of ghrelin (ghrelin) was 79% compared to the control, and the content of ghrelin was lower than 20%, and quercetin was 90% compared to the control. Showed relatively high ghrelin (ghrelin) content. Compared with the control in all treatments, the content of ghrelin was reduced, and it was confirmed that the effect of suppressing appetite.
  • UAVEC Human umbilical vein endothelial cell
  • sibutramine a positive control, had a content of 75% (25% inhibition) at a concentration of 1 ug / ml, and high ghrelin at 68% (32% inhibition) at 10 ug / ml.
  • Inhibitory activity was ascorbic acid (ascorbic acid) showed a secretion rate of 93% and 94% at concentrations of 1 ug / ml and 10 ug / ml, respectively.
  • the concentration of ghrelin decreased as the concentration of sample increased in concentration-dependent manner, showing the lowest content of 85% at the concentration of 10 ug / ml, and 1 ug / for hesperetin.
  • the highest inhibitory activity was shown to be 79%, and low value of 85% even at 10 ug / ml.
  • Melatonin had a low ghrelin content of 87% at 10 ug / ml, and ginsenoside-Rb1 gradually decreased with increasing concentrations to 76% at 10 ug / ml.
  • Ginsenoside-Rg1 (ginsenoside-Rg1) also showed a tendency to decrease the content of ghrelin in a concentration-dependent manner, showing a low content of 84% at 10 ug / ml.
  • 3 and 4 show the content of ghrelin according to the heating temperature of the food ingredient.
  • the cell proliferation ability according to the temperature was found to maintain the overall cell proliferation ability even when the temperature is increased to 60 ⁇ 100 °C.
  • the content of ghrelin according to the temperature change is maintained stably.
  • Ghrelin (ghrelin) is mostly 80 ⁇ 90% in the temperature range of 60 ⁇ 100 °C it was judged that the inhibitory effect is maintained about 20 to 10%. From this, even when the food ingredients are heated, cell proliferation and ghrelin inhibitory activity is maintained, thereby indirectly confirming the possibility of maintaining appetite suppressing activity of the food ingredients during processing.
  • the content of ghrelin was investigated according to the pH change of food ingredients under acidic, neutral, and basic conditions (FIGS. 5 and 6).
  • the residual amount of ghrelin was similar to that of the temperature treatment because the residual amount of ghrelin was lower than that of the control in all treatments even when pH 2, 7 and 10 were changed in the food ingredients. From this, it was indirectly determined that the appetite suppression effect was maintained overall by suppressing ghrelin activity even when ingesting food components in the body.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Botany (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une composition alimentaire de coupe-faim qui comporte un composé spécifique en tant que principe actif. Plus particulièrement, la présente invention concerne une composition et un aliment ayant une fonction de coupe-faim, qui comportent au moins un ingrédient choisi dans le groupe constitué par l'hespérétine, le ginsénoside-Rb1, la 3-hydroxyflavone, l'hespéridine, le ginsénoside-Rg1, le β-D-glucane, la rutine, la flavanone, la naringine, la mélatonine, la quercétine et l'acide ascorbique, cet ingrédient présentant un effet coupe-faim par diminution de l'activité de la ghréline, qui est une hormone de stimulation de l'appétit.
PCT/KR2010/008111 2010-09-17 2010-11-16 Composition alimentaire de coupe-faim comportant un composé spécifique en tant que principe actif WO2012036344A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR1020100091517A KR101155426B1 (ko) 2010-09-17 2010-09-17 식욕억제 식품성분 조성물
KR10-2010-0091517 2010-09-17
KR1020100108541A KR101250198B1 (ko) 2010-11-03 2010-11-03 특정 화합물을 유효성분으로 포함하는 식욕억제 식품성분 조성물
KR10-2010-0108541 2010-11-03

Publications (1)

Publication Number Publication Date
WO2012036344A1 true WO2012036344A1 (fr) 2012-03-22

Family

ID=45831783

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2010/008111 WO2012036344A1 (fr) 2010-09-17 2010-11-16 Composition alimentaire de coupe-faim comportant un composé spécifique en tant que principe actif

Country Status (1)

Country Link
WO (1) WO2012036344A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2990036A1 (fr) * 2014-07-30 2016-03-02 Symrise AG Hydroxyflavones pour stimulation d'appétit
EP3303566B1 (fr) * 2015-06-03 2020-10-14 Takara Bio Europe AB Maturation d'hépatocytes de mammifères

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001062108A1 (fr) * 2000-02-22 2001-08-30 Suzanne Jaffe Stillman Eau contenant des fibres solubles
WO2009008714A1 (fr) * 2007-07-06 2009-01-15 Dsm Ip Assets B.V. Compositions alimentaires

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001062108A1 (fr) * 2000-02-22 2001-08-30 Suzanne Jaffe Stillman Eau contenant des fibres solubles
WO2009008714A1 (fr) * 2007-07-06 2009-01-15 Dsm Ip Assets B.V. Compositions alimentaires

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WILLIAMSON, G. ET AL.: "Polyphenol content and health benefits of raisins", NUTRITION RESEARCH, vol. 30, no. 8, August 2010 (2010-08-01), pages 511 - 519 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2990036A1 (fr) * 2014-07-30 2016-03-02 Symrise AG Hydroxyflavones pour stimulation d'appétit
EP3303566B1 (fr) * 2015-06-03 2020-10-14 Takara Bio Europe AB Maturation d'hépatocytes de mammifères
US10913932B2 (en) 2015-06-03 2021-02-09 Takara Bio Europe Ab Maturation of mammalian hepatocytes

Similar Documents

Publication Publication Date Title
WO2015026114A1 (fr) Composition contenant un composé monoacétyldiglycéride en tant que principe actif pour la prévention ou le traitement de l'arthrite rhumatoïde
WO2018117659A1 (fr) Composition pharmaceutique comprenant un extrait de levis pulverata indigo ou une fraction de celui-ci comme principe actif pour prévenir ou traiter une maladie intestinale inflammatoire
WO2013105693A1 (fr) Composition pharmaceutique comprenant un extrait de cortex d'oryza sativa l. et d'hordeum vulgare var. hexastichon comme principe actif
WO2016076607A2 (fr) Composition pharmaceutique et aliment fonctionnel pour la santé, contenant un concentré de ginseng rouge avec un composé enrichi en composant k, pour la prévention et le traitement du symptôme de la stéatose hépatique d'origine non alcoolique
WO2016186349A2 (fr) Composition, contenant un extrait de quisaqualis indica, pour la prévention ou le traitement de l'hyperplasie prostatique
WO2012036344A1 (fr) Composition alimentaire de coupe-faim comportant un composé spécifique en tant que principe actif
WO2017073849A1 (fr) Composition pour la prévention ou le traitement de l'arthrite, contenant un extrait de sargassum serratifolium en tant que substance active
WO2013129714A1 (fr) Composition pharmaceutique pour la prévention ou le traitement de la fibrose hépatique et de la cirrhose, contenant de la ramaline
WO2016167444A1 (fr) Composition pharmaceutique destinée à prévenir ou à traiter l'obésité ou des maladies métaboliques lipidiques, contenant un extrait d'atractylodis macrocephalae rhizoma
KR101358197B1 (ko) 특정 화합물을 유효성분으로 포함하는 렙틴 분비 촉진용 조성물
WO2012091492A2 (fr) Extrait de plantes, composition pharmaceutique comprenant celui-ci et aliment fonctionnel diététique comprenant celle-ci
WO2018008973A1 (fr) Composition comprenant un extrait de forsythiae fructus en tant que principe efficace pour prévenir, améliorer ou traiter la neuropathie périphérique
WO2017111429A1 (fr) Composition pour le traitement du syndrome de sécheresse oculaire, contenant un extrait d'airelle noire en tant que substance active
KR101250198B1 (ko) 특정 화합물을 유효성분으로 포함하는 식욕억제 식품성분 조성물
KR101155426B1 (ko) 식욕억제 식품성분 조성물
WO2019083264A1 (fr) Composition pour prévenir, soulager ou traiter des maladies du foie, contenant un produit fermenté d'extrait de germe de ginseng vieilli en tant que substance active
WO2018190631A1 (fr) Composition destinée à prévenir, améliorer ou traiter la dépression par diminution de la sécrétion d'œstrogènes, contenant un extrait de tetragonia tetragonioides à titre de principe actif
WO2024106846A1 (fr) Composition comprenant un extrait de suaeda glauca en tant que principe actif pour la prévention, le soulagement ou le traitement d'une maladie hépatique
WO2020017921A1 (fr) Composition pharmaceutique de prévention ou de traitement de la sarcopénie, contenant un extrait de salicorne d'europe
WO2018226060A1 (fr) Composition pour la prévention ou le traitement d'une maladie rénale contenant de la cudratricusxanthone a ayant une activité de protection des reins à titre de principe actif
KR101271478B1 (ko) 3-히드록시플라본, 헤스페리딘, 케르세틴, 카테킨 및 카페인을 유효성분으로 포함하는 렙틴 분비 촉진용 조성물
WO2023121334A1 (fr) Composition comprenant un extrait de cardamine flexuosa en tant que principe actif pour la prévention, l'atténuation ou le traitement d'une maladie respiratoire
KR20120029985A (ko) 식욕억제 기능성 음료조성물
WO2016195256A1 (fr) Composition pharmaceutique destinée à prévenir et à traiter l'obésité ou les maladies hépatiques, contenant un agoniste du tlr7
WO2024096261A1 (fr) Composition pour la prévention ou le traitement de maladies auto-inflammatoires et utilisations correspondantes

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10857329

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10857329

Country of ref document: EP

Kind code of ref document: A1